Interaction between oral estrogen plus progestogen therapy and ABO blood groups on coagulation activation in postmenopausal women

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Menopause

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/gme.0b013e31822b721fPMID 22089178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ย่อเอกสาร : Risk and benefits of estrogen plus progestin in healthy postmenopausal women

  2012cited by this paper
• Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy

  2011cited by this paper
• Postmenopausal hormone therapy and venous thromboembolism.

  2011cited by this paper
• Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women

  2010cited by this paper
• Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study.

  2010cited by this paper
• Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study

  2010cited by this paper
• Reproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology

  2010cited by this paper
• Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk

  2010cited by this paper
• Hormone replacement therapy and the risk of venous thromboembolism: a population‐based study

  2010cited by this paper
• PAI-1 and D-Dimer in Type 2 Diabetic Women With Asymptomatic Macrovascular Disease Assessed by Carotid Doppler

  2010cited by this paper
• Hormone therapy and risk of venous thromboembolism among postmenopausal women

  2009cited by this paper
• The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women

  2009cited by this paper
• Mechanisms of thrombosis related to hormone therapy.

  2009influential reference
• Polymorphisms in exons 6 and 7 of the ABO locus and their association with venous thrombosis in young Brazilian patients

  2009cited by this paper
• Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy

  2009cited by this paper
• Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

  2008cited by this paper
• Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor

  2008cited by this paper
• Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system

  2007influential reference
• The differential effect of estrogen, estrogen–progestin and tibolone on coagulation inhibitors in postmenopausal women

  2007cited by this paper
• Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study

  2007cited by this paper
• Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.

  2007cited by this paper
• Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.

  2007cited by this paper
• Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study

  2007cited by this paper
• Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women.

  2007cited by this paper
• Changes in Hemostatic Variables Induced by Estrogen Replacement Therapy: Comparison of Transdermal and Oral Administration in a Crossover-Designed Study

  2007cited by this paper
• ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens

  2007cited by this paper
• ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?

  2006cited by this paper
• The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women

  2006influential reference
• Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.

  2006cited by this paper
• Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals

  2005cited by this paper
• ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden

  2005cited by this paper
• Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review

  2005cited by this paper
• Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.

  2005influential reference
• Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic tools.

  2005influential reference
• Estrogen plus progestin and risk of venous thrombosis.

  2005cited by this paper
• Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case–control study

  2005cited by this paper
• Low-dose oral combination of 17β-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1

  2004cited by this paper
• Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension.

  2004cited by this paper
• Estrogen plus progestin and risk of venous thrombosis.

  2004cited by this paper
• Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels.

  2004cited by this paper
• An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13

  2003cited by this paper
• Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.

  2003cited by this paper
• Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women

  2003cited by this paper
• A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women.

  2002influential reference
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Menopausal Symptoms in Older Women and the Effects of Treatment With Hormone Therapy

  2002cited by this paper
• Different Effects of Oral and Transdermal Hormone Replacement Therapies on Factor IX, APC Resistance, t-PA, PAI and C-reactive Protein

  2001influential reference
• Elevated Factor VIII Levels and the Risk of Thrombosis

  2001cited by this paper
• Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial

  2001influential reference
• Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women

  2001cited by this paper
• High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.

  2000cited by this paper
• Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time.

  2000cited by this paper
• Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.

  2000influential reference
• The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature.

  2000influential reference
• Effect of estrogen‐progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women

  1998cited by this paper

• Genome-wide Association Study of Estradiol Levels and the Causal Effect of Estradiol on Bone Mineral Density

  2021cites this paper
• Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy.

  2018cites this paper
• Contraception and Venous Thromboembolism: Risk Factors and Clinical Considerations

  2017cites this paper
• The Role of ABO Blood Type in Thrombosis Scoring Systems

  2017cites this paper
• Menstrual Cycle: Evaluation of Hematological Changes

  2017cites this paper
• Prevention and treatment of venous thromboembolism during HRT: current perspectives

  2014cites this paper
• ABO blood group polymorphisms and risk for ischemic stroke and peripheral arterial disease

  2014cites this paper
• The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy

  2013cites this paper
• Preeclampsia and ABO blood groups: a systematic review and meta-analysis

  2012cites this paper